Literature DB >> 27308602

Diagnostic implications of intrapatient genetic tumor heterogeneity.

Ana P Berbegall1, Samuel Navarro1, Rosa Noguera1.   

Abstract

The complex genetic composition of neuroblastoma emphasizes the importance of conscientious and meticulous diagnosis. Clones with amplification or segmental chromosomal aberrations sometimes remain hidden. Several determinations should be performed when sufficient tumor material is available to establish the final diagnosis by combining the results of different techniques on tumor fragments or liquid biopsies.

Entities:  

Keywords:  Heterogeneous MYCN amplification; heterogeneous segmental chromosome aberration; intratumoral genetic heterogeneity; neuroblastoma; spatial intrapatient genetic heterogeneity; temporal genetic heterogeneity

Year:  2015        PMID： 27308602      PMCID： PMC4905381          DOI： 10.1080/23723556.2015.1079671

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.

Authors:  Michael W Bishop; Hong Yin; Hiroyuki Shimada; Alexander J Towbin; Alexander Miethke; Brian Weiss
Journal:  J Pediatr Hematol Oncol       Date:  2014-01       Impact factor: 1.289

2.  Emergence of new ALK mutations at relapse of neuroblastoma.

Authors:  Gudrun Schleiermacher; Niloufar Javanmardi; Virginie Bernard; Quentin Leroy; Julie Cappo; Thomas Rio Frio; Gaelle Pierron; Eve Lapouble; Valérie Combaret; Frank Speleman; Bram de Wilde; Anna Djos; Ingrid Ora; Fredrik Hedborg; Catarina Träger; Britt-Marie Holmqvist; Jonas Abrahamsson; Michel Peuchmaur; Jean Michon; Isabelle Janoueix-Lerosey; Per Kogner; Olivier Delattre; Tommy Martinsson
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

3.  Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.

Authors:  P F Ambros; I M Ambros; R Kerbl; A Luegmayr; S Rumpler; R Ladenstein; G Amann; H Kovar; E Horcher; B De Bernardi; J Michon; H Gadner
Journal:  Med Pediatr Oncol       Date:  2001-01

4.  Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Authors:  A P Berbegall; E Villamón; M Piqueras; I Tadeo; A Djos; P F Ambros; T Martinsson; I M Ambros; A Cañete; V Castel; S Navarro; R Noguera
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

5.  MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.

Authors:  Ruediger Spitz; B Hero; M Skowron; K Ernestus; F Berthold
Journal:  Eur J Cancer       Date:  2004-12       Impact factor: 9.162

6.  Alternative pathways of MYCN gene copy number increase in primary neuroblastoma tumors.

Authors:  Alexander Valent; Marine Guillaud-Bataille; Chantal Farra; François Lozach; Barbara Spengler; Marie-José Terrier-Lacombe; Dominique Valteau-Couanet; Gisèle Danglot; Gilbert M Lenoir; Olivier Brison; Jean Bénard; Alain Bernheim
Journal:  Cancer Genet Cytogenet       Date:  2004-08

7.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

Authors:  Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

8.  Heterogeneity of the MYCN oncogene in neuroblastoma.

Authors:  Jessica Theissen; Marc Boensch; Ruediger Spitz; David Betts; Sabine Stegmaier; Holger Christiansen; Felix Niggli; Freimut Schilling; Manfred Schwab; Thorsten Simon; Frank Westermann; Frank Berthold; Barbara Hero
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Authors:  Eva Villamón; Ana P Berbegall; Marta Piqueras; Irene Tadeo; Victoria Castel; Anna Djos; Tommy Martinsson; Samuel Navarro; Rosa Noguera
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.

Authors:  P F Ambros; I M Ambros; G M Brodeur; M Haber; J Khan; A Nakagawara; G Schleiermacher; F Speleman; R Spitz; W B London; S L Cohn; A D J Pearson; J M Maris
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640
  10 in total
  2 in total

1.  Advancing Clinicopathologic Diagnosis of High-risk Neuroblastoma Using Computerized Image Analysis and Proteomic Profiling.

Authors:  M Khalid Khan Niazi; Jonathan H Chung; Katherine J Heaton-Johnson; Daniel Martinez; Raquel Castellanos; Meredith S Irwin; Stephen R Master; Bruce R Pawel; Metin N Gurcan; Daniel A Weiser
Journal:  Pediatr Dev Pathol       Date:  2017-04-18

2.  Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Authors:  Ana P Berbegall; Dominik Bogen; Ulrike Pötschger; Klaus Beiske; Nick Bown; Valérie Combaret; Raffaella Defferrari; Marta Jeison; Katia Mazzocco; Luigi Varesio; Ales Vicha; Shifra Ash; Victoria Castel; Carole Coze; Ruth Ladenstein; Cormac Owens; Vassilios Papadakis; Ellen Ruud; Gabriele Amann; Angela R Sementa; Samuel Navarro; Peter F Ambros; Rosa Noguera; Inge M Ambros
Journal:  Br J Cancer       Date:  2018-05-14       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.